ReviewCancers2022
Treatment of Neuropathic Pain Directly Due to Cancer: An Update.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Brazilian Society of Surgical Oncology: Guidelines and Consensus Statement for Palliative Surgery in Oncology.Journal of surgical oncology · 2026Guideline
- Efficacy and Security of Tetrodotoxin in the Treatment of Cancer-Related Pain: Systematic Review and Meta-Analysis.Marine drugs · 2023Pooled it
- Evaluation of Novel Cloxyquin Analogs for KArchiv der Pharmazie · 2026Article
- A prospective multimethod investigation of cancer-related pain integrating clinical data and machine learning: results from the RUGGI Study.Journal of anesthesia, analgesia and critical care · 2026Article
- Review
- Structure-Function Relationships of KAdvances in experimental medicine and biology · 2026Review
- Breaking Through Cancer Pain: From Single-Drug Management to Multimodal Analgesia.Pain research & management · 2026Review
- Pharmacological Management of Cancer Pain: Advances in Treatment Strategies and Drug Delivery Systems.Pharmaceutics · 2025Review
- MRI-guided focused ultrasound thalamotomy for neuropathic pain in an adolescent with cranial metastases: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Causes and management of acute oncological pain: a narrative review.Anaesthesia · 2025Review
- Verapamil and venlafaxine combined as an effective and well-tolerated adjunct for cancer pain management.American journal of translational research · 2025Article
- Construction and validation of a nomogram to identify risk of sleep disorders in gastrointestinal tumor patients undergoing chemotherapy.American journal of translational research · 2025Article
- Complication avoidance, rehabilitation, pain therapy and palliative care for patients with metastatic spine tumors: WFNS spine committee recommendations.Neurosurgical review · 2024Review
- Exploring the Therapeutic Potential of N-Methyl-D-Aspartate Receptor Antagonists in Neuropathic Pain Management.International journal of molecular sciences · 2024Review
- Negative allosteric modulation of CBNeuropharmacology · 2024Article
- Comprehensive assessment of pain characteristics, quality of life, and pain management in cancer patients: a multi-center cross-sectional study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Neuropathic Pain in Cancer: What Are the Current Guidelines?Current treatment options in oncology · 2024Review
- Foundations for a Personalized Psycho-Oncology: The State of the Art.Journal of personalized medicine · 2024Review
- Targeting TRPV4 Channels for Cancer Pain Relief.Cancers · 2024Review
- Trends in Pregabalin Use and Prescribing Patterns in the Adult Population: A 10-Year Pharmacoepidemiologic Study.CNS drugs · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain can be defined as pain related to abnormal somatosensory processing in either the peripheral or central nervous system. In this review article, with neuropathic cancer pain (NCP), we refer to pain due to nervous tissue lesions caused by the tumor or its metastases. Nervous tissue damage is the cause of cancer pain in approximately 40% of those experiencing cancer pain. Recognizing a neuropathic pathophysiology in these cases may be difficult and requires specific criteria that are not homogenously applied in clinical practice. The management of this type of pain can be challenging, requiring the use of specific non-opioid adjuvant drugs. The majority of the criteria for NCP diagnosis and management have been based mainly on results from the noncancer population, risking the failure of addressing the specific needs of this population of patients. In this review, we summarize current management options available for NCP and provide some insights on new promising treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.